HomeCompareCHSYF vs MRK

CHSYF vs MRK: Dividend Comparison 2026

CHSYF yields 2.81% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $35.6K in total portfolio value
10 years
CHSYF
CHSYF
● Live price
2.81%
Share price
$1.35
Annual div
$0.04
5Y div CAGR
-21.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$27.60
Full CHSYF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CHSYF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHSYFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHSYF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHSYF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHSYF
Annual income on $10K today (after 15% tax)
$239.26/yr
After 10yr DRIP, annual income (after tax)
$23.46/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,304.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHSYF + MRK for your $10,000?

CHSYF: 50%MRK: 50%
100% MRK50/50100% CHSYF
Portfolio after 10yr
$39.0K
Annual income
$4,912.87/yr
Blended yield
12.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CHSYF
No analyst data
Altman Z
10.1
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHSYF buys
0
MRK buys
0
No recent congressional trades found for CHSYF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHSYFMRK
Forward yield2.81%2.76%
Annual dividend / share$0.04$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-21.3%32.7%
Portfolio after 10y$21.2K$56.8K
Annual income after 10y$27.60$9,798.13
Total dividends collected$979.00$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHSYF vs MRK ($10,000, DRIP)

YearCHSYF PortfolioCHSYF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,922$221.53$11,206$366.19$284.00MRK
2$11,864$177.95$12,650$502.35$786.00MRK
3$12,837$142.18$14,407$694.19$1.6KMRK
4$13,848$113.15$16,585$967.82$2.7KMRK
5$14,908$89.78$19,342$1,363.89$4.4KMRK
6$16,022$71.09$22,913$1,947.19$6.9KMRK
7$17,200$56.19$27,662$2,823.89$10.5KMRK
8$18,448$44.37$34,159$4,173.35$15.7KMRK
9$19,775$35.00$43,337$6,308.80$23.6KMRK
10$21,186$27.60$56,776$9,798.13$35.6KMRK

CHSYF vs MRK: Complete Analysis 2026

CHSYFStock

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.

Full CHSYF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CHSYF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHSYF vs SCHDCHSYF vs JEPICHSYF vs OCHSYF vs KOCHSYF vs MAINCHSYF vs JNJCHSYF vs ABBVCHSYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.